GHRP-6: Side Effects

Safety Notice#

GHRP-6 is not approved for therapeutic use in any country. The side effect information below is derived from clinical research studies and is provided for educational purposes only.

Growth Hormone-Related Side Effects#

Many of the side effects associated with GHRP-6 are secondary to its intended pharmacological action — the stimulation of growth hormone release. These GH-mediated effects are generally the same as those observed with exogenous GH administration:

Fluid Retention#

Water retention is one of the most commonly reported effects of GH stimulation. This occurs because GH promotes sodium and water reabsorption in the kidneys. Symptoms may include mild edema (particularly in the hands and feet), joint stiffness, and mild weight gain. These effects are typically dose-dependent and resolve with dose reduction or discontinuation.

Paresthesias#

Tingling, numbness, or burning sensations in the extremities (paresthesias) have been reported in some subjects receiving GH secretagogues. The mechanism may involve GH-mediated effects on peripheral nerve function, carpal tunnel compression from fluid retention, or changes in nerve conduction. These symptoms are usually mild and transient.

Insulin Resistance#

Growth hormone is a counter-regulatory hormone to insulin, and GH stimulation can impair insulin sensitivity. While this effect is minimal with short-term GHRP-6 use, chronic GH stimulation could theoretically contribute to impaired glucose tolerance. This is a particular concern in individuals with pre-existing insulin resistance or diabetes.

GHRP-6 Specific Side Effects#

Appetite Stimulation#

The most characteristic non-GH side effect of GHRP-6 is a pronounced increase in appetite. This occurs because GHRP-6 activates the same receptor (GHS-R1a) as ghrelin, the endogenous "hunger hormone." The appetite-stimulating effect typically occurs within 20-30 minutes of administration and can last 1-2 hours. The intensity of hunger stimulation is greater with GHRP-6 than with most other GHS peptides, making it less suitable for individuals seeking to avoid increased caloric intake.

Cortisol and Prolactin#

GHRP-6 stimulates modest increases in both cortisol and prolactin secretion in addition to GH. These effects are dose-dependent and transient:

• Cortisol: Typically increases 20-50% above baseline, returning to normal within 1-2 hours. This level of cortisol elevation is not considered clinically significant for acute use but could be relevant with chronic high-dose administration.
• Prolactin: Increases of 20-100% above baseline have been observed, depending on dose. While usually clinically insignificant, persistent prolactin elevation could theoretically affect reproductive function.

These non-GH hormonal effects distinguish GHRP-6 from more selective GHS compounds like ipamorelin, which produces minimal cortisol or prolactin changes.

Long-Term Safety Considerations#

Chronic Administration#

The long-term safety of repeated GHRP-6 administration in humans has not been thoroughly evaluated. Key concerns include:

• GH axis desensitization: Partial tachyphylaxis (reduced GH response over time) has been observed with chronic GHRP-6 use, though significant GH-releasing activity is maintained
• IGF-1 elevation: Chronic GH stimulation would elevate IGF-1 levels, which has been epidemiologically associated with increased cancer risk in some studies
• Metabolic effects: Long-term GH stimulation could affect glucose homeostasis, lipid metabolism, and body composition

Cancer Considerations#

Growth hormone and IGF-1 have been associated with increased cancer risk in epidemiological studies. While GHRP-6 stimulates physiological pulsatile GH release rather than continuous supraphysiological levels, the theoretical concern about promoting malignancies remains. GHRP-6 should be avoided in individuals with active or recent malignancies.

Comparison of Side Effect Profiles#

Related Reading#

• GHRP-6 overview and research guide
• GHRP-6 dosing protocols
• GHRP-6 risks and legal status